You can inject Repatha into the abdomen, thigh, or upper arm. It’s injected subcutaneously (under the skin). If you’re injecting it into your upper arm, you may need a family member or caregiver to ...

Only inject Repatha (evolocumab) on its scheduled day. Do not inject a dose in advance. The timing of your Repatha dose on an injection day isn’t important, so you can adjust it as needed on that day.

Both Repatha and Praluent are used to treat high cholesterol and reduce the risk of certain cardiovascular events. The drugs also have different approved uses in adults and children. Repatha and ...

More common side effects of Repatha may include cold and flu-like symptoms, back pain, and injection site reactions. Mild Repatha side effects also include headache, fatigue, stomach cramping, and ...

AbbVie’s Qulipta (atogepant tablets) has been approved for the preventive treatment of episodic migraine in adults. In the pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled, ...

How Does Repatha Work for High Cholesterol? People can have high cholesterol for a number of reasons, including their diet, exercise habits, or genetic conditions. Keeping your cholesterol low, ...

Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...

THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...

The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH. The Food and Drug Administration (FDA) has approved Repatha (evolocumab) injection as an adjunct to ...

THOUSAND OAKS, Calif. (Nov. 13, 2020) - Amgen (NASDAQ:AMGN) today announced a new analysis from the Repatha® (evolocumab) cardiovascular (CV) outcomes study (FOURIER) that evaluated the effectiveness ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...